⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AGEN News
Agenus Inc.
A Agenus anuncia a inclusão do primeiro paciente no estudo global de fase 3 BATTMAN, que avalia a combinação de imunoterapia BOT+BAL em câncer colorretal metastático MSS ou pMMR
businesswire.com
AGEN
Agenus kondigt inschrijving eerste patiënt aan voor wereldwijde Fase 3 BATTMAN-studie naar BOT+BAL-immunotherapiecombinatie bij MSS- of pMMR-gemetastaseerde colorectale kanker
businesswire.com
AGEN
Agenus宣布BOT+BAL聯合免疫療法用於MSS或pMMR轉移性大腸直腸癌的全球第三期BATTMAN試驗完成首例病患招募
businesswire.com
AGEN
Agenus宣布BOT+BAL联合免疫疗法用于MSS或pMMR转移性结直肠癌的全球3期BATTMAN试验完成首例患者入组
businesswire.com
AGEN
Agenus gibt die Aufnahme des ersten Patienten in die globale Phase-3-Studie BATTMAN bekannt, in der die Immuntherapie-Kombination aus BOT und BAL bei metastasiertem kolorektalem Karzinom der MSS- oder pMMR-Gruppe untersucht wird
businesswire.com
AGEN
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer
businesswire.com
AGEN
Agena Bioscience Announces Launch of the CFTR 100+ Panel on the MassARRAY ® System
businesswire.com
AGEN
Form 8-K
sec.gov
AGEN
Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer
businesswire.com
AGEN
Form 8-K
sec.gov
AGEN